Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.
September 2018

Endocyte Completes $201.3 Million Public Offering

Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, completed a $201.3 million public offering of common stock. Our firm advised Endocyte on the transaction. Endocyte's shares trade on the NASDAQ Global Market under the symbol "ECYT."

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.